Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens

Kamel, Mohamed S.; El-Sayed, Amr

doi:10.1016/j.virusres.2019.197648

Cited by 27 publications

(24 citation statements)

References 183 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with non-viral vectors, the transfection rate and immunogenicity of the viral vector are both higher, but the vector is more toxic, the capacity of the target gene is smaller, the targeting specificity is worse, the preparation is more complicated, and the cost is higher. Compared with viral vectors, non-viral vectors feature an ease of production, high yield, and low cost, and they can be widely used for drug delivery [174][175][176][177][178]. Chitosan derivative nanoparticles, as non-viral vectors, have excellent solubility, biodegradability, biocompatibility, non-toxicity, and a higher transfection rate than chitosan nanoparticles [73,98,179].…”

Section: Chitosan Derivative Nanoparticles For the Delivery Of Genementioning

confidence: 99%

Chitosan Derivatives and Their Application in Biomedicine

Wang

Meng

et al. 2020

IJMS

605

326

View full text Add to dashboard Cite

Chitosan is a product of the deacetylation of chitin, which is widely found in nature. Chitosan is insoluble in water and most organic solvents, which seriously limits both its application scope and applicable fields. However, chitosan contains active functional groups that are liable to chemical reactions; thus, chitosan derivatives can be obtained through the chemical modification of chitosan. The modification of chitosan has been an important aspect of chitosan research, showing a better solubility, pH-sensitive targeting, an increased number of delivery systems, etc. This review summarizes the modification of chitosan by acylation, carboxylation, alkylation, and quaternization in order to improve the water solubility, pH sensitivity, and the targeting of chitosan derivatives. The applications of chitosan derivatives in the antibacterial, sustained slowly release, targeting, and delivery system fields are also described. Chitosan derivatives will have a large impact and show potential in biomedicine for the development of drugs in future.

show abstract

Section: Chitosan Derivative Nanoparticles For the Delivery Of Genementioning

confidence: 99%

Chitosan Derivatives and Their Application in Biomedicine

Wang

Meng

et al. 2020

IJMS

605

326

View full text Add to dashboard Cite

show abstract

“…The strain has been used worldwide for nearly 60 years for its safety, and it has the potential to become a mammalian vaccine carrier ( 18 ). In the genome, gE, gI, and TK genes are virulence-related genes but not necessary for replication ( 43 , 44 ). Knockout of these genes can reduce the virulence of the virus, and these sites can serve as insertion sites for heterologous genes.…”

Section: Discussionmentioning

confidence: 99%

Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing SARS-CoV-2-S and SARS-CoV-2-N

Shao

Xie

et al. 2022

Front. Vet. Sci.

View full text Add to dashboard Cite

Coronavirus (CoV) is an important pathogen of humans and animals, which can infect humans or animals through the respiratory mucosal route. Syndrome coronavirus 2 (SARS-CoV-2) is quite similar to syndrome coronavirus (SARS-CoV) with the same receptor, angiotensin-converting enzyme 2 (ACE2). The S and N proteins are the most important protective antigens of the SARS-CoV-2. The S protein on the viral membrane mediates the virus attachment with the host cells, and the N protein is the most abundant expression during infection. In this study, the recombinant viruses expressing the S and N proteins of SARS-CoV-2 were successfully constructed by Red/ET recombinant technology using Pseudorabies virus (PRV) strain Bartha-K61 as a vector. Genetic stability and growth kinetics analysis showed that the recombinant viruses rPRV-SARS-CoV-2-S and rPRV-SARS-CoV-2-N had similar genetic stability and proliferation characteristics to the parental PRV. The immunoassay results showed that mice immunized with recombinant viruses could produce total IgG antibodies. Therefore, PRV is feasible and promising as a viral vector to express SARS-CoV-2-S and SARS-CoV-2-N genes. This study can provide a reference for future research on live vector vaccines for domestic animals, pets, and wild animals.

show abstract

“…Compared to other kinds of virus vectors, such as Marek’s disease virus or adenovirus, NDV has a small genomic RNA, which just encodes six proteins (NP-P-M-F-HN-L), so there will be little influence on the expression and immunization of the exogenous protein [ 35 , 36 , 37 ]. In theory, foreign genes can be inserted into the sequences between any two genes of NDV.…”

Section: Discussionmentioning

confidence: 99%

Generation and Evaluation of Recombinant Thermostable Newcastle Disease Virus Expressing the HA of H9N2 Avian Influenza Virus

Zhang

Meng

et al. 2021

Viruses

View full text Add to dashboard Cite

H9N2 avian influenza virus (AIV) has become endemic in many countries, causing great economic losses when co-infected with other pathogens. So far, several live vaccines based on Newcastle disease virus (NDV) vectors expressing influenza hemagglutinin (HA) have been developed. However, the thermostable recombinant NDV is rarely reported. In this study, using a thermostable NDV rAHR09 strain as the vector, three recombinant NDVs expressing native HA, chimeric HA ectodomain with transmembrane domain/C-terminal cytoplasmic tail domain from fusion protein of NDV, and HA ectodomain were generated, designated rAHR09-HA, rAHR09-HAF, and rAHR09-HAE. The MDT value of three recombinant NDVs was above 120 h, their ICPI value was about 0.03, and the recombinant NDVs were still infectious when treated for 100 min under 56 °C, which demonstrated that the recombinant NDVs kept the lentogenic and thermostable nature of rAHR09. The immunization data showed that rAHR09-HA and rAHR09-HAF induced a higher HI antibody titer against H9N2 AIV and NDV. After being challenged with H9N2 AIV, the rAHR09-HA and rAHR09-HAF could significantly reduce the virus shedding in cloacal and tracheal swab samples. Our results suggest that rAHR09-HA and rAHR09-HAF might be vaccine candidates against H9N2 AIV.

show abstract

Utilization of herpesviridae as recombinant viral vectors in vaccine development against animal pathogens

Cited by 27 publications

References 183 publications

Chitosan Derivatives and Their Application in Biomedicine

Chitosan Derivatives and Their Application in Biomedicine

Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing SARS-CoV-2-S and SARS-CoV-2-N

Generation and Evaluation of Recombinant Thermostable Newcastle Disease Virus Expressing the HA of H9N2 Avian Influenza Virus

Contact Info

Product

Resources

About